Cancer antigen-125 is a predictor of mortality in patients with pulmonary arterial hypertension |
| |
| Affiliation: | 1. Cardiology Department, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey;2. Cardiology Department, Canakkale Onsekiz Mart University, Canakkale, Turkey;3. Anesthesiology and Reanimation Department, Sivas Cumhuriyet University, Sivas, Turkey;1. Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, PR China;2. Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai 200032, PR China;3. Department of Laboratory Medicine, Xiamen Branch, Zhongshan Hospital, Fudan University, 668 Jin Hu Road, Xiamen 361015, PR China;4. Department of Laboratory Medicine, Wusong Branch, Zhongshan Hospital, Fudan University, 101 Tong Tai North Road, Shanghai 200940, PR China;1. DynaLIFE Medical Labs and University of Alberta Department of Laboratory Medicine and Pathology, Edmonton, AB, Canada;2. St Michael’s Hospital and University of Toronto Department of Medicine, Toronto, ON, Canada;3. Sunnybrook Hospital and University of Toronto Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada;4. St Michael’s Hospital and University of Toronto Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada;1. Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey;2. Department of Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey;3. Department of Physiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey;4. Department of Public Health, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey;1. Clinical Laboratory, Hospital Universitari de Sant Joan d’Alacant, Sant Joan d’Alacant, Spain;2. Department of Clinical Medicine, Universidad Miguel Hernández, Elche, Spain;3. Department of Biochemistry and Molecular Pathology, Universidad Miguel Hernandez, Elche, Spain;4. CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain;5. Department of Radiology, University of Missouri, Columbia, MO, USA;1. Post-Graduation Program in Biological Sciences: Toxicological Biochemistry, Center of Natural and Exact Sciences of the Federal University of Santa Maria, Santa Maria, RS, Brazil;2. Graduate Program in Biomedical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil;3. Medical School, Federal University of Fronteira Sul, Chapecó, SC, Brazil;4. Physical Activity Group, Physical Education Center, Federal University of Santa Maria, Santa Maria, RS, Brazil;1. Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, United States;2. ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, United States |
| |
| Abstract: | BackgroundCarbohydrate antigen 125 (CA 125), known as a tumor marker for ovarian cancer, has been reported to increase and be associated with severity in heart failure and chronic obstructive pulmonary disease. Patients with pulmonary arterial hypertension may also die due to developing right heart failure. The aim of this study is to evaluate the prognostic role of CA-125 in PAH patients.MethodsA total of 40 consecutive patients with PAH were evaluated prospectively. The mean age of patients was 52 ± 11 years (12% males, 88% females) with a median follow-up period of 16 months.ResultsAfter follow-up period, 12 out of 40 patients (30%) died. CA-125 levels were higher among those who died compared to those who survived [78.5 (11.0–292) vs. 27.5 (2.10–138) U/ml, p = 0.001]. The optimal cut-off value of CA-125 to predict mortality was found as 35.29 U/ml, with 85.7% specificity and 75% sensitivity. In multivariable Cox proportional-hazards model with forward stepwise method; CA-125 > 35.32 U/ml on admission (HR = 7.645, 95% CI: 1.356–43.121, p = 0.021), age (HR = 1.132, 95% CI: 1.040–1.233, p = 0.004), TAPSE (HR = 0.740, 95% CI: 0.549–0.998, p = 0.048) and uric acid (HR = 1.444, 95% CI: 1.022–2.042, p = 0.037) remained associated with an increased risk of death.ConclusionIn this study, we showed for the first time that serum CA-125 values were an independent predictor for the long-term mortality in PAH patients. |
| |
| Keywords: | Pulmonary arterial hypertension CA 125 antigen Mortality Biomarker |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
